創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 20/01/29 | GEM147 | Insulin | Diabetes | Oral | Peptide | Preclinical | GEM147 is a nanoencapsulation of insulin in biodegradable polymer nanospheres. Nanoencapsulation protects insulin during stomach passage. In vivo, statistically significant reduction in blood glucose was seen in diabetic rats with oral GEM147 within 30 minutes. | 問合せ |
| 20/01/29 | GEM146 | VD Receptor | Prostate cancer, Autoimmune diseases | i.v. | Small molecule | Preclinical | GEM146 is a nanosomal formulation of AMPI-109, a nontoxic Vitamin D3 analog. In vivo studies have shown strong anticancer effects of GEM146 against Hormone Refractory Prostate Cancer xenografts in nude mice at doses approximately 6.5 times less than the parent hormone, without significant toxicity. | 問合せ |
| 20/01/29 | GEM145 | 5-HT | Chemotherapy Induced Nausea and Vomiting （CINV) | Oral | Small molecule | Phase 2/3 | Acute vomiting was blocked effectively by 5-HT3 anti-emetics plus the adjuvant Emend® but no benefits were observed in terms of the incidence of nausea . Phase 2/3 clinical trial on GEM145 as an adjuvant to conventional 5-HT3 anti-emetics was completed (more than 600 cancer patients). All doses of GEM145 significantly reduced acute nausea severity compared to the placebo (p=0.003). | 問合せ |
| 20/01/29 | GEM144 | PKC modulator plus HDAC inhibitor | HIV Latency | i.v., Oral | Small molecule | Phase 2a | GEM144 is a nanoencapsulation of PKC modulators plus HDAC inhibitor in targeted, pegylated phospholipid nanosomes for improved therapeutic index. Activates HIV from latent reservoirs so that HIV can be eradicated from the body by antiviral therapy and/or immune system. |
問合せ |
| 20/01/29 | GEM143 | CB1, CB2, 5-HT1a | Multiple Sclerosis（MS), Opioid addiction, Chemotherapy induced Peripheral Neuropathic Pain（CIPNP), and Epilepsy | Oral | Small molecule | Preclinical | GEM143 is a nanoencapsulation of the API in biodegradable polymer nanospheres for improved oral bioavailability. MS: The API has multiple actions on key molecular neuroinflammation and neurodegeneration targets, with highly effective in vitro and in vivo bioactivities. Opioid addiction: The API is not an opioid and has been shown to alleviate cue-induced opioid addiction behaviors and allosterically modulate the μ and δ-opioid receptors. CIPNP: Nanoencapsulation is being used to protect the API during the stomach passage. Epilepsy: The API is an effective anti-convulsant with a specificity more comparable to drugs clinically effective in major seizures. |
問合せ |
| 20/01/20 | GEM142 | Nrf2 Activator | COPD and Diabetic kidney disease | Oral | Small molecule | Phase 1 | A novel Nrf2 activator. Inhibited airway inflammation to a similar degree as roflumilast in a mouse smoke exposure model. Improved urinary albumin/creatinine ratio in STZ-induced rat diabetic model (Type I) and KK-Ay mouse (Type II) and inhibited damage of the renal tissues. Synergistic effects by combination with losartan on urinary albumin/creatinine ratio were noted in KK-Ay mice. No adverse events were seen in multiple dose phase 1 study even at 1000 mg/man/day. | 問合せ |
| 20/01/16 | GEM141 | Esophageal implant (See note) | Pediatric esophageal atresia and other conditions that affect the esophagus | Implant （auto- logous) | Cell therapy | IND ready | Esophageal implant made by combining a novel cell therapy platform (see TGEM38) with a patient’s own cells (haematopoietic stem and precursor cells). GEM141 leverages the body’s inherent capacity to heal itself as it is a “living tube” that facilitates regeneration of esophageal tissue and triggers a positive host response resulting in a tissue-engineered neo-conduit that restores continuity of the esophagus. These implants have the potential to dramatically improve the quality of life for children and adults | 問合せ |
| 20/01/08 | GEM140 | Limbal stem cells | Intractable limbal stem cell deficiency | Implan- tation | Cell therapy | Clinical | Establishment and production of limbus-derived epithelial cell plate manufacturing process in GMP facility with excellent economic feasibility. Phase 1 study is currently in progress. |
問合せ |
| 20/01/08 | GEM139 | Staphylococcus aureus vaccine | Staphylococcus aureus infection | s.c. | Vaccine | Preclinical | The vaccine comprising antigens and toxin is being developed. The candidate antigens to block the immune-evasion pathway by MSCRAMMs and toxin of S. aureus have already been defined. | 問合せ |
| 19/12/24 | GEM138 | Biosimilar adalimumab | Same indications as adalimumab | i.v. | Antibody | Preclinical | Purified GEM138 is highly similar to adalimumab by SDS-PAGE. GEM138 and adalimumab show a similar response in a TNF-a ELISA assay. Plant-based technology (TGEM036) was applied for production of GEM138. | 問合せ |